CRL vs FCRX · rev $4.02B vs P/E 177, $132.8M cap
Charles River Laboratories (CRL) versus First Eagle Alternative Capital BDC Inc (FCRX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
First Eagle Alternative Capital BDC Inc (FCRX) common stock listed on NYSE.
Latest reported CRL revenue for 2025-12-27 was $4.02B. Net income was -$144.3M. CRL currently screens at market cap $7.78B.
FCRX does not have a complete income-statement cache yet.
CRL currently screens at market cap $7.78B. FCRX currently screens at market cap $132.8M and trailing P/E 177.3.
Not investment advice. Open the CRL and FCRX stock pages for the full models.
Not investment advice.